ArticleJournal of thoracic disease2025
A new mouse model of biomass smoke-related chronic obstructive pulmonary disease combining porcine pancreatic elastase nebulization.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biomass smoke exposure (BME) is an independent risk factor for chronic obstructive pulmonary disease (COPD), particularly among women and children in developing countries. Existing animal models of biomass smoke-related COPD are limited due to prolonged modeling periods. This study aimed to develop a novel composite protocol for constructing a biomass smoke-related COPD mouse model using porcine pancreatic elastase nebulization. Methods: Six-week-old female C57BL/6 mice (n=6 per group) were exposed to porcine pancreatic elastase nebulization on the first day and biomass smoke for the remaining 6 days of each week over a 4-month period. Pulmonary function, histopathology, and inflammatory markers were assessed via pulmonary function tests, Hematoxylin & eosin (H&E) staining, enzyme-linked immunosorbent assay (ELISA) and multiplexed liquid chip analysis respectively. Results: BME induced significant pulmonary function impairment, characterized by increased functional residual capacity (FRC), quasi-static compliance, and static compliance, alongside reduced a ratio of forced expiratory volume at 100 ms and forced vital capacity (FEV100/FVC), dynamic pulmonary compliance as well. Histopathological analysis revealed emphysema and bronchiectasis in lung tissue. Elevated levels of interleukin-1β (IL-1β) and interleukin-10 (IL-10) were observed in the BME group, with a concurrent increase in plasma interleukin-2 (IL-2). In the BME group, mitogen-activated protein kinase 1 (MAPK1) expression increased, whilst expression of signal transducer and activator of transcription 3 (STAT3) decreased. Additionally, matrix metalloproteinase-9 (MMP9) expression decreased. Conclusions: The results of this study indicate that BME significantly induced pulmonary function injury leading to emphysema and bronchiectasis changes, as well as systemic inflammation. IL-10 may play a significant role in the pro-inflammatory/anti-inflammatory mechanisms of COPD by regulating the expression of key signalling pathway proteins. A novel COPD modeling method incorporating elastase was constructed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.